The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
DRI DIETARY REFERENCE INTAKES FOR Vitamin C, Vitamin E, Selenium, and Carotenoids
U.S. physicians reported no significant effect of 12 years of supplementation of β-carotene (50 mg every other day) on cancer or total mortality (Hennekens et al., 1996).
Summary. Higher consumption of carotenoid-containing fruits and vegetables and higher plasma concentrations of several carotenoids, including β-carotene, are associated with a lower risk of many different cancers, especially lung, oral cavity, pharyngeal, laryngeal, and cervical cancers. These prospective blood concentration studies show that β-carotene concentrations in the range of 0.28 µmol/L (15 µg/dL) or less are associated with higher risk of many cancers (Table 8-3), whereas concentrations greater than 0.28 to 0.37 µmol/L (15 to 20 µg/dL) are associated with reduced risk of many cancers. This approximate threshold for cancer risk reduction is concordant with that for the prevention of all-cause mortality, given above. Furthermore, these studies show that increased consumption of foods containing these carotenoids, including carotenoids lacking vitamin A activity, is associated with risk reduction. However, in three large randomized clinical trials using high-dose β-carotene supplements (20 or 30 mg/day or 50 mg given every other day) for 4 to 12 years, no protection was reported with respect to lung cancer, or any other cancer.
Epidemiological studies, including descriptive, cohort, and case-control studies, suggest that carotenoid- and β-carotene-rich diets are associated with a reduced risk of cardiovascular disease (Gaziano and Hennekens, 1993; Kohlmeier and Hastings, 1995; Manson et al., 1993). Beginning with biochemical epidemiological studies of plasma carotenoids, Gey et al. (1993a) reported data from the Vitamin Substudy of the World Health Organization's Monitoring Cardiovascular (WHO/MONICA) Project, in which plasma was obtained from approximately 100 apparently healthy men from each of 16 study sites within Europe. A comparison between median plasma β-carotene concentrations and ischemic heart disease mortality revealed no association when all 16 study sites were considered (r2 = 0.04). However, a reasonably strong inverse association was evident (r2 = 0.50) when three study sites, all apparent outliers (and all Finnish sites), were excluded from the analysis.
Men in the Basel Prospective Study, who had low blood concentrations of β-carotene and vitamin C initially and who were followed for 12 years, had a significantly higher risk of subsequent ischemic